All In Biotech

Drug Trial Radar · NCT07940777

A Study to Evaluate the Safety and Efficacy of Mavacamten in Adults With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (SOLSTICE-HCM)

A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Safety and Efficacy of Mavacamten in Adults With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (SOLSTICE-HCM)

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Dec 29, 2026

Primary completion

Jul 21, 2029

Study completion Jul 19, 2032

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Nov 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to evaluate the safety and efficacy of Mavacamten in adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (SOLSTICE-HCM)

Conditions

  • Non-obstructive Hypertrophic Cardiomyopathy

Interventions

  • MavacamtenDrug

    Specified dose on specified days

  • PlaceboOther

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Peak Oxygen Consumption (pVO2)Time frame: At Week 48
  2. Change from baseline in Kansas City Cardiomyopathy Questionnaire, 23-item (KCCQ-23 CSS)Time frame: At Week 48

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.